Development of an EEG Diagnostic for Alzheimer's Disease

• Conditions: Mild Cognitive Impairment; Alzheimer Disease; Normal Control APOE e4 Carriers and Noncarriers; Dementia With Lewy Bodies

• Registration Number: NCT04954183
• Lead Sponsor: Mayo Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-6-29
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Inclusion Criteria:<br><br> - 5 individuals with moderate to severe dementia, 5 with mild stage dementia, 5 with<br> amnestic MCI, 5 presymptomatic APOE e4 carriers, and 5 age, sex, and education<br> matched APOE e4 noncarriers. Additionally we will include a group of 5 patients with<br> mild to moderate stage dementia with Lewy bodies (DLB), the second most common<br> degenerative dementia, to explore differences from clinically typical Alzheimer's<br> disease patients given the known clinical differences in EEG dysrhythmic severity<br> between them (total of 30).<br><br> - Unimpaired APOE e4/4 homozygotes age 65-75 and APOE e3/4 heterozygotes age 75-85 for<br> the preclinical AD subset and age, sex, and education matched APOE e4 noncarriers<br> for the unaffected controls.<br><br> - Biomarker confirmation for preclinical diagnosis will be utilized to the extent<br> possible (a subset of 130 members of our cohort have undergone amyloid-PET resulting<br> in approximately 45 who are amyloid positive).<br><br>Exclusion Criteria:<br><br> - Previous stroke.<br><br> - Severe head injury.<br><br> - Craniotomy.<br><br> - Any other potentially confounding neurologic illness (typically anything that causes<br> structural brain damage).<br><br> - Psychoactive medication use will not be an absolute exclusionary criterion in<br> patients with moderate to severe dementia but patients who are relatively drug-free<br> will be prioritized to the extent they are available within the study period.<br><br> - Psychoactive drug use will be exclusionary in the prospectively obtained clinical<br> patients.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Obtain electroencephalogram (EEG) data